OGOleg A. Gerasimov

Oleg A. Gerasimov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oleg A. Gerasimov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Anastasia Piniaeva

    Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow 108819, Russia

    1 shared publication
  • Anastasiya A. Kovpak

    Chumakov FSC R&D IBP RAS (Institute of Poliomyelitis), Building 1, Village of the Institute of Poliomyelitis 8, Municipal District Filimonkovskiy, Moscow 108819, Russia

    1 shared publication
  • Anna Zyrina

    Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow 108819, Russia

    1 shared publication
  • Aydar A. Ishmukhametov

    Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow 108819, Russia

    1 shared publication
  • Dmitry V. Danilov

    Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences

    1 shared publication
  • Irina O. Tcelykh

    Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia

    1 shared publication

Latest Publications

  • Open Access

    Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography

    by Anastasia A. Kovpak, Anastasia N. Piniaeva, Oleg A. Gerasimov, Irina O. Tcelykh, Mayya Y. Ermakova, Anna N. Zyrina, Dmitry V. Danilov, Yury Y. Ivin, Liubov I. Kozlovskaya, Aydar A. Ishmukhametov

    Various types of COVID-19 vaccines, including adenovirus, mRNA, and inactivated ones, have been developed and approved for clinical use worldwide. Inactivated vaccines are produced using a proven technology that is widely used for the production of vaccines for the prevention and control of infectious diseases, including influenza and poliomyelitis. The development of inactivated whole-virion vaccines commonly includes several stages: the production of cellular and viral biomass in cell culture; inactivation of the virus; filtration and ultrafiltration; chromatographic purification of the viral antigen; and formulation with stabilizers and adjuvants. In this study, the suitability of four resins for Size-Exclusion Chromatography was investigated for the purification of a viral antigen for the human COVID-19 vaccine.